peptide garden
Menu
News

FDA Proposes to Permanently Exclude Compounded Semaglutide, Tirzepatide, and Liraglutide

FDA's April 30, 2026 proposal would bar 503B outsourcing facilities from compounding three GLP-1 drugs from bulk substances on a finding of no clinical need. Here is what it does — and does not — change.

·8 min read·Regulatory

On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the catalog of bulk drug substances that registered outsourcing facilities are permitted to compound from when there is a clinical need.[1] The proposal rests on a finding that there is no, or insufficient, clinical need for these three GLP-1 drugs to be compounded from bulk substances now that the FDA-approved products are widely available.

The notice was published in the Federal Register on May 1, 2026 (91 Fed. Reg. 23431; FR Doc. 2026-08552).[2] It is a proposal, not a final rule — the agency is taking public comment before it decides.

  • What it is: A proposal to leave three GLP-1 drugs off the 503B bulks list on a finding of no/insufficient clinical need.
  • Who it targets: Large-scale 503B outsourcing facilities compounding from bulk drug substances — not individual telehealth prescriptions.
  • If finalized: An absolute, forward-looking bar for 503B facilities — re-nomination foreclosed even if a future shortage recurs.
  • What it is not: It is not the April 1, 2026 "essentially a copy" 503A clarification, and not the February 2026 shortage-list removal.
  • Comments due: July 30, 2026. FDA extended the original deadline by 30 days on June 26, 2026 (FR Doc 2026-12937). Docket: FDA-2018-N-3240.

Quick facts

Announced
April 30, 2026
Federal Register
May 1, 2026
FR citation
91 Fed. Reg. 23431
FR document
2026-08552
Drugs affected
Semaglutide, tirzepatide, liraglutide
Pathway affected
503B (outsourcing facilities)
Basis
No/insufficient clinical need
Comments due
July 30, 2026 (extended)

What the 503B bulks list actually governs

To understand this proposal, it helps to separate the two kinds of compounding pharmacies, which we cover in detail in our explainer on what compounding pharmacies are.

503B outsourcing facilities are larger, FDA-registered operations that can make compounded drugs in bulk without a patient-specific prescription. They may compound from a bulk drug substance — raw active pharmaceutical ingredient — only in two situations: when the FDA-approved drug is in shortage, or when the substance appears on the 503B bulks list because the FDA has found a clinical need for it.

503A pharmacies are traditional pharmacies that compound for an individual patient against a specific prescription. They operate under a different set of rules.

This proposal is about the 503B bulks list, and only the 503B bulks list. The FDA reviewed the nominations it received to add semaglutide, tirzepatide, and liraglutide to that list and concluded it had not identified sufficient evidence of clinical need — so the agency is proposing to leave all three off.[1][2]

When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.

— FDA Commissioner Marty Makary[1]

Why "permanent" — and why it is stricter than a shortage ending

When a drug comes off the FDA shortage list, compounding does not stop because of a finding about the drug itself — it stops because the temporary legal basis (the shortage) has gone away. If a shortage recurred, that basis could return.

A clinical-need exclusion works differently. If this proposal is finalized, the three GLP-1 drugs would be formally excluded from the 503B bulks list on the merits. For 503B facilities, that creates an absolute, forward-looking bar to compounding them from bulk substances — and, per legal analyses of the notice, it forecloses re-nomination, even if a future shortage of the approved products were to recur.[3][4]

In plain terms: a shortage ending is a door that can reopen. A clinical-need exclusion is closer to bricking up the doorway.

The honest distinction. This proposal targets large-scale 503B bulk compounding. It does not, by itself, end individual 503A compounding, and it does not by itself stop a telehealth provider from writing a patient-specific prescription. Those are governed by separate rules and separate FDA actions. Conflating them is the most common error in coverage of this proposal.

What it does not change

This is the part most worth slowing down on, because the headlines blur three separate FDA actions that happened within weeks of each other.

  • It is not the April 1, 2026 "essentially a copy" clarification. That action concerned 503A compounding and the rules around making something that is essentially a copy of a commercially available drug. It is a different pathway and a different legal test.
  • It is not the February 2026 shortage-list removal. That action removed the shortage-based justification. This proposal is a separate, merits-based finding about the bulks list.
  • It does not announce an immediate ban on individual telehealth GLP-1 prescriptions. 503A pharmacies retain only narrow, patient-specific exceptions even absent a shortage — for example, a documented allergy to an inactive ingredient in the branded product, or a clinically justified dose strength that is not commercially available. Patient preference and cost savings alone do not qualify.[3]

If you are a patient currently receiving a compounded GLP-1, the practical takeaway is not "this is banned tomorrow." It is that the legal runway for large-scale compounded supply continues to narrow, and that the patient-specific exceptions that remain are genuinely narrow.

The safety record FDA is citing

The proposal sits against a backdrop of adverse-event reporting that the FDA has used to argue the risks of compounded versions outweigh a (now contested) clinical need.

As of early 2025, the FDA had received more than 455 adverse-event reports associated with compounded semaglutide and more than 320 associated with compounded tirzepatide.[1] Many of these traced to dosing errors with multidose vials, where patients self-measuring from a vial drew up the wrong amount — a class of error largely designed out of the single-dose, pre-filled pens used for the approved products.

Read these figures carefully. The 455+ and 320+ totals are FDA figures as of early 2025 — they are not a new May 2026 tally. Adverse-event reports also do not establish causation on their own; they are signals, not verdicts. We cite them because the FDA cites them, not to imply a settled risk quantification.

The market was already contracting

Even before this proposal, trade-press reporting described the supply side thinning out as the shortage that justified compounding resolved and FDA enforcement intensified.

  • ProRx and BPI Labs — both 503B outsourcing facilities — halted GLP-1 production in April 2026.
  • Medisource stopped in March 2026.
  • Olympia Pharmaceuticals had already exited in 2025.

The proposal would formalize, on the merits, a contraction that market forces and earlier enforcement had largely set in motion.[6]

How the compounding industry is responding

The Alliance for Pharmacy Compounding (APC), the main trade group for compounders, has framed the proposal as one that "does not change the status quo" for 503B facilities — because under existing law those facilities were already limited to compounding these drugs during a shortage, and the shortage has ended.[5] In other words, by APC's reading, the proposal codifies a constraint that was already operative rather than imposing a new one. APC has said it is reviewing the proposal and will submit comments.

That framing is worth holding alongside the legal analyses above: both can be true. The proposal may not change what 503B facilities can do today (already shortage-limited), while still changing what they could ever do tomorrow (foreclosing the bulks-list route permanently).

How to comment

This is a proposal in an open comment period, which means public input is part of the process.

On June 26, 2026, the FDA extended the comment period by 30 days, moving the deadline from June 30 to July 30, 2026 (FR Doc 2026-12937). Comments are filed under standing docket FDA-2018-N-3240.[7]

  • The public comment window now closes July 30, 2026.
  • The regulations.gov docket FDA-2018-N-3240 is authoritative for the exact deadline and the submission mechanism — confirm there before relying on any third-party date.[2]

What this means for you

Three things are simultaneously true, and the honest version of this story holds all three:

  1. For large-scale 503B bulk compounding of these GLP-1s, the door is closing — and, if finalized, closing permanently on a clinical-need finding rather than a temporary shortage basis.
  2. This is not, by itself, an immediate ban on every compounded or telehealth GLP-1 prescription. 503A pathways and narrow patient-specific exceptions persist, and a separate set of FDA actions governs them.
  3. The approved products remain available, which is precisely the FDA's stated rationale for finding no clinical need to compound from bulk.

If you currently use a compounded GLP-1, this is a moment to talk with your prescriber about transitioning to an FDA-approved option, and to track the live regulatory picture rather than any single headline. We maintain a legal-status tracker that follows these actions as they move from proposal to final rule, and our earlier report on semaglutide compounding under scrutiny traces how the supply and legal picture got here.

For the full evidence profiles — mechanism, trials, safety, and approval status — see our pages on semaglutide, tirzepatide, and liraglutide.

References

  1. [1]
    U.S. Food and Drug Administration. “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List.” 2026. Linkguideline

    FDA press announcement, April 30, 2026. Primary agency source for the proposal and the Commissioner Makary quote.

  2. [2]
    U.S. Food and Drug Administration. “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act.” Federal Register. 2026. 91 Fed. Reg. 23431 Linkguideline

    Federal Register notice, published May 1, 2026; FR Doc. 2026-08552. The regulations.gov docket linked from this notice is the authoritative source for the comment deadline.

  3. [3]
    Orrick, Herrington & Sutcliffe LLP. “FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs.” 2026. LinkReview

    Law firm analysis of the proposal's scope, including the narrow 503A patient-specific exceptions and the distinction from prior shortage-list actions.

  4. [4]
    Epstein Becker Green. “FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List.” 2026. LinkReview

    Legal analysis of the clinical-need framework under section 503B and the forward-looking effect of an exclusion finding.

  5. [5]
    Alliance for Pharmacy Compounding. “FDA moves to exclude three GLP-1s from 503B compounding.” 2026. Linkother

    Trade-association statement framing the proposal as not changing the status quo for 503B facilities, which are already shortage-limited. APC says it is reviewing and will comment.

  6. [6]
    Pharmacy Times. “FDA Moves to Permanently Close the Door on Compounded GLP-1s.” 2026. Linkother

    Trade-press coverage corroborating the proposal's scope and the supply-side contraction among outsourcing facilities.

  7. [7]
    U.S. Food and Drug Administration. “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B; Extension of Comment Period.” Federal Register. 2026. Linkguideline

    Federal Register notice published June 26, 2026; FR Doc. 2026-12937. Extends the comment period 30 days, to July 30, 2026, under docket FDA-2018-N-3240.

Stay informed

Get evidence-based peptide updates. No spam, no vendor pitches — just the research and regulatory changes that matter.

Related content

Peptide

Semaglutide

The GLP-1 agonist behind Ozempic and Wegovy — one of the three drugs named in the proposal. Mechanism, trials, and approval status.

Peptide

Tirzepatide

The dual GIP/GLP-1 agonist behind Mounjaro and Zepbound — also named in the proposal. Full research profile.

Peptide

Liraglutide

The daily GLP-1 agonist behind Victoza and Saxenda — the third drug in the proposal. Evidence and status.

News

Semaglutide Compounding Under Scrutiny

How GLP-1 supply normalization and mounting lawsuits set the stage for this regulatory action.

News

What Are Compounding Pharmacies?

The 503A vs. 503B distinction that this proposal turns on, explained plainly.

Disclaimer

This article is for educational purposes only and is not legal or medical advice. It describes an FDA proposal that is open for public comment and not a final rule; details may change before any final determination. The regulations.gov docket for FR Doc. 2026-08552 is the authoritative source for deadlines and procedure. Always consult a licensed healthcare provider before making decisions about any medication, and a qualified attorney for regulatory questions.